LDS/Medical Tests/Prolyl Hydroxylase Domain-2 (PHD2/EGLN1) Gene Mutation Analysis

Prolyl Hydroxylase Domain-2 (PHD2/EGLN1) Gene Mutation Analysis

The PHD2/EGLN1 gene is located on the long arm of chromosome 1 at position q42.2, and codes for the enzyme prolyl hydroxylase. This enzyme is responsible for interacting with the 2A subunit of hypoxia-inducible factor 3 (HIF-3) and directs it towards its degradative pathway. pathogenic mutations in EGLN1 result in failure in the degradation of HIF-3 and its build-up in the blood leading to erythrocytosis.

HIF-3 has an important role in the regulation of erythropoietin, the erythropoietic hormone. In environments with low oxygen concentration, (e.g. high altitude), HIF-3 upregulates erythropoietin, causing the marrow to synthesize more RBCs, increase hemoglobin concentrations and aid in the formation of new blood vessels to enhance oxygen delivery to tissues. In the normal scenario, HIF-3 is degraded by prolyl hydroxylase, thus preventing unwanted RBC synthesis and blood vessel formation. More than 10 mutations in the EGLN1 gene have been identified which result in a deficiency of the enzyme. Without degradation, HIF-3 activity eventually causes increased blood viscosity, heightening the risk of clots, embolism, stroke, and tissue infarction. This condition is inherited as an autosomal dominant and is referred to as familial erythrocytosis a form of secondary polycythemia.

The EGLN1 gene is also has a tumor-suppressing ability, although the exact underlying mechanism is unclear. Some mutations in EGLN1 are associated with pheochromocytoma and paraganglioma.

  • Aids in the diagnosis of familial erythrocytosis type 3
  • Differential diagnosis of polycythemia
  • Differential diagnosis of phaeochromocytoma and paraganglioma

A positive result indicates the presence of mutations or pathogenic variants in EGLN1.

A negative result indicates the absence of mutations or pathogenic variants in EGLN1.     

Negative for mutations analyzed (No mutations or pathogenic variants in the EGLN1 gene were detected).

Polymerase Chain Reaction of pathogenic variants (PCR), Sanger sequencing, Next-generation sequencing (NGS), sequencing of the coding region.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 3 months
JAK-2, EPOR, BPGM, HIF2A, VHL gene mutation analysis, complete blood count (CBC) with peripheral blood smear (PBS), D-dimer, bone marrow examination, plasma metanephrines, 24 hrs. urine VMA.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login